Gilead Sciences, Inc. (GILD) EVP Sells $2,370,000.00 in Stock
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the sale, the executive vice president now directly owns 57,114 shares in the company, valued at approximately $4,512,006. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up $1.23 during trading hours on Tuesday, hitting $80.25. 11,750,000 shares of the stock traded hands, compared to its average volume of 8,040,000. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The company has a market cap of $104,800.00, a PE ratio of 9.13, a PEG ratio of -1.68 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the business earned $2.75 EPS. The business’s quarterly revenue was down 13.2% on a year-over-year basis. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
A number of brokerages have recently issued reports on GILD. Wells Fargo & Co raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $79.02 to $96.00 in a report on Tuesday. Leerink Swann raised their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Mizuho raised their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, CIBC began coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They set a “market perform” rating on the stock. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $85.61.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Capital Asset Advisory Services LLC bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $875,000. Factory Mutual Insurance Co. raised its position in shares of Gilead Sciences by 4.6% during the second quarter. Factory Mutual Insurance Co. now owns 586,000 shares of the biopharmaceutical company’s stock valued at $41,477,000 after buying an additional 26,000 shares during the last quarter. Prentiss Smith & Co. Inc. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $497,000. Hellman Jordan Management Co. Inc. MA bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $839,000. Finally, First American Bank raised its position in shares of Gilead Sciences by 19.9% during the second quarter. First American Bank now owns 74,301 shares of the biopharmaceutical company’s stock valued at $5,259,000 after buying an additional 12,352 shares during the last quarter. Institutional investors own 75.95% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.